Ivonescimab Receives China Approval for EGFR-Mutated NSCLC, Demonstrates Superior Efficacy Across Multiple Cancer Types

China's National Medical Products Administration (搜索)搜索该词条 approved ivonescimab查看药品详情 in May 2024 for treating patients with EGFR (搜索)搜索该靶点-mutated locally advanced or metastatic non-squamous NSCLC (搜索)搜索该疾病 who have progressed after tyrosine kinase inhibitor therapy. This bispecific antibody, developed by Akeso Biopharma (搜索)搜索该词条, represents a significant advancement in cancer immunotherapy by simultaneously targeting both PD-1 (搜索)搜索该靶点 and VEGF (搜索)搜索该靶点 pathways.

Breakthrough Mechanism of Action

Ivonescimab查看药品详情 employs a unique tetravalent structure that enables cooperative binding between its dual targets. The drug forms soluble complexes with VEGF (搜索)搜索该靶点 dimers, which accelerates binding kinetics to PD-1 (搜索)搜索该靶点 and results in an 18-fold higher binding affinity compared to conventional monoclonal antibodies like penpulimab. This cooperative mechanism means that VEGF presence actually enhances the drug's PD-1 blockade activity.

The antibody's Fc region has been engineered with double mutation L234A/L235A to minimize binding to FcγRI/IIIa receptors, substantially reducing Fc-mediated effector functions including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This modification may contribute to reduced immune-related adverse events while maintaining therapeutic efficacy.

Clinical Efficacy Across Cancer Types

EGFR-Mutated NSCLC Success

A global Phase III trial (NCT05184712查看临床试验) involving 322 participants demonstrated ivonescimab查看药品详情's superior efficacy in EGFR (搜索)搜索该靶点-mutated NSCLC (搜索)搜索该疾病. Patients receiving ivonescimab plus chemotherapy achieved a median progression-free survival of 7.06 months compared to 4.80 months for chemotherapy alone (HR 0.46). The objective response rate reached 50.6% versus 35.4% in the placebo group.

Subgroup analyses revealed consistent benefits across patient populations, including those with brain metastases (HR 0.40), EGFR (搜索)搜索该靶点 19 deletion mutations (HR 0.48), and T790M mutations (HR 0.22). The intracranial response rate for the ivonescimab查看药品详情-chemotherapy combination was 39% with a 25% complete response rate.

First-Line NSCLC Treatment

In a randomized Phase III trial (NCT05499390查看临床试验) comparing ivonescimab查看药品详情 versus pembrolizumab查看药品详情 in PD-L1 (搜索)搜索该靶点-positive NSCLC (搜索)搜索该疾病, ivonescimab significantly prolonged median progression-free survival (11.1 vs 5.8 months). The drug demonstrated higher response rates with 50% versus 39% objective response rate and 90% versus 71% disease control rate compared to pembrolizumab.

Patients with hepatic metastases showed particularly pronounced improvement with ivonescimab查看药品详情 (median PFS: 7.1 vs 2.7 months), indicating that adding VEGF (搜索)搜索该靶点 inhibition to PD-1 (搜索)搜索该靶点 blockade enhances efficacy in this challenging subgroup.

Promising Results in Other Cancer Types

Triple-Negative Breast Cancer (搜索)搜索该疾病: A Phase 2 study (NCT05227664查看临床试验) in 30 patients showed an investigator-assessed objective response rate of 72.4% with 100% disease control rate. Patients with PD-L1 (搜索)搜索该靶点 CPS ≥10 achieved 83.3% response rate, while those with CPS <10 had 69.6% response rate.

Small Cell Lung Cancer (搜索)搜索该疾病: A Phase Ib trial in 35 treatment-naïve extensive-stage SCLC patients demonstrated 80% overall response rate and 91.4% disease control rate. The 10 mg/kg dose group showed the highest efficacy with 90.9% response rate.

Biliary Tract Cancer (搜索)搜索该疾病: An ongoing Phase 1b/2 study (NCT052114482) in 22 patients with advanced biliary tract cancer showed 63.6% objective response rate and 100% disease control rate, with median progression-free survival of 8.5 months and median overall survival of 16.8 months.

Metastatic Colorectal Cancer (搜索)搜索该疾病: A randomized Phase II trial (NCT05382442查看临床试验) in 40 patients showed objective response rates of 81.8% and 88.2% in different treatment arms, with 100% disease control rate in both groups.

Safety Profile and Management

Ivonescimab查看药品详情 demonstrated a manageable safety profile consistent with known toxicities of PD-L1 (搜索)搜索该靶点 and VEGF (搜索)搜索该靶点 inhibitors. The most common treatment-related adverse events included proteinuria, elevated aspartate aminotransferase, hypercholesterolemia, neutropenia, and hypertension.

Immune-related adverse events occurred at higher rates with ivonescimab查看药品详情 (24.2% vs 6.2% placebo), with the most frequent grade ≥3 events being rash, dermatitis, interstitial lung disease, and hepatic dysfunction. VEGF (搜索)搜索该靶点 inhibition-related adverse events included grade ≥3 hypertension (5% vs 1%) and proteinuria (3% vs 0%).

Pharmacokinetic Properties

Pharmacokinetic studies showed dose-proportional increases in serum levels within the 3-30 mg/kg range, with steady-state concentrations achieved by week 15. The drug's elimination half-life was 9.85 days, with clearance declining from 0.461 L/day initially to 0.334 L/day at steady state.

High levels of PD-1 (搜索)搜索该靶点 receptor occupancy (>80%) were maintained at doses of 3.0 mg/kg and above, while serum-free VEGF (搜索)搜索该靶点 concentrations dropped significantly by 80-95% within 24 hours after the initial dose across all cohorts.

Future Development

Five Phase III clinical studies are currently underway, including two international multicenter trials conducted overseas. The drug has been included in China's national medical insurance program as of November 2024, improving patient access to this innovative therapy.

The success of ivonescimab查看药品详情 validates the bispecific antibody approach for combining checkpoint blockade with anti-angiogenic therapy, potentially paving the way for similar dual-target strategies in oncology. Its unique cooperative binding mechanism and engineered safety profile position it as a significant advancement in cancer immunotherapy.